{ "items": [ "\n\n
\n \n 22 April 2022\n \n
\n\n \n\n \n\n \n \n \n \n COMRU\n \n \n \n \n MORU\n \n \n\n \n\n\n
\n \n\n \n \n \nIn regions where few people have received Covid-19 vaccines, health systems remain vulnerable to surges in SARS-CoV-2 infections. During the delta-wave of COVID-19 in India, for example, healthcare facilities and staff across the country struggled to cope with the surge in the number of cases of COVID-19 due to a shortage of hospital beds for people with severe cases, plus shortages of medicines and limited human resources.
\n \n\n\n \n 19 April 2022\n \n
\n\n \n\n \n\n \n \n \n \n KWTRP\n \n \n\n \n\n\n
\n \n\n \n \n \nDr Emelda Okiro has been awarded the prestigious Wellcome Senior Research Fellowship. Emelda\u2019s fellowship is the first African Senior Research Fellowship awarded in the KEMRI-Wellcome Research Programme and among the less than five SRFs awarded to researchers in Africa.
\n \n\n\n \n 13 April 2022\n \n
\n\n \n\n \n\n \n \n \n \n KWTRP\n \n \n\n \n\n\n
\n \n\n \n \n \nYoung children in sub-Saharan Africa and South Asia who become sick or malnourished continue to have a high risk of death in the six months after being hospitalized, according to findings by researchers in the Childhood Acute Illness & Nutrition (CHAIN) Network. Appearing in The Lancet Global Health, the study of 3,101 acutely ill children at nine hospitals in six countries across sub-Saharan Africa and South Asia found that 48% of the 350 deaths recorded occurred within six months after discharge from hospital.
\n \n\n\n \n 6 April 2022\n \n
\n\n \n\n \n\n \n \n \n \n OUCRU\n \n \n \n \n OUCRU-Indonesia\n \n \n\n \n\n\n
\n \n\n \n \n \nWhat do we mean by 'Research Culture' and how has fostering a multinational, collaborative culture helped us deliver world-class research? Let's explore the research culture at OUCRU.
\n \n\n\n \n 1 April 2022\n \n
\n\n \n\n \n\n \n \n \n \n NDM-CGHR\n \n \n\n \n\n\n
\n \n\n \n \n \nThe Global Research on Antimicrobial Resistance (GRAM) Project has a new centre of operations at the University of Oxford, after moving this month from the Big Data Institute to the Centre for Tropical Medicine and Global Health, under the leadership of Dr. Benn Sartorius (PI) and Prof. Christiane Dolecek (co-PI).
\n \n\n\n \n 29 March 2022\n \n
\n\n \n\n \n\n \n \n \n \n NDM-CGHR\n \n \n\n \n\n\n
\n \n\n \n \n \nThe Indian Council for Medical Research (ICMR) National Institute of Malaria Research (NIMR) and IDDO collaborate on a joint capacity building venture to train young researchers across three infectious diseases: malaria, visceral leishmaniasis and lymphatic filariasis
\n \n\n\n \n 29 March 2022\n \n
\n\n \n\n \n\n \n \n \n \n KWTRP\n \n \n \n \n Public Engagement\n \n \n\n \n\n\n
\n \n\n \n \n \nMonitoring and Evaluation helps us keep track of our public engagement activities and outcomes. KEMRI -Wellcome Trust recently completed a report detailing our experiences and learning.
\n \n\n\n \n 29 March 2022\n \n
\n\n \n\n \n\n \n \n \n \n NDM-CGHR\n \n \n\n \n\n\n
\n \n\n \n \n \nWWARN researchers have been assessing the recommended minimum follow-up period in capturing polymerase chain reaction (PCR)-confirmed recrudescence following treatment with fixed-dose artemisinin combination therapies (ACTs) for patients with uncomplicated Plasmodium falciparum malaria.
\n \n\n\n \n 29 March 2022\n \n
\n\n \n\n \n\n \n \n \n \n NDM-CGHR\n \n \n\n \n\n\n
\n \n\n \n \n \nThe RECOVERY Trial begins testing the antiviral treatment Paxlovid. Paxlovid, an oral antiviral treatment developed by Pfizer, is a combination of nirmatrelvir and ritonavir. Nirmatrelvir inhibits an enzyme that is critical for the replication of the virus that causes COVID-19, whilst ritonavir increases the concentration of nirmatrelvir.
\n \n\n\n \n 29 March 2022\n \n
\n\n \n\n \n\n \n \n \n \n OUCRU\n \n \n \n \n OUCRU-Indonesia\n \n \n \n \n Public Engagement\n \n \n \n \n Video\n \n \n\n \n\n\n
\n \n\n \n \n \nWhy does OUCRU place an important focus on engaging with its important partners, policy makers, the press, the community, and young people? Explore our work in policy & public engagement.
\n \n\n\n \n 28 March 2022\n \n
\n\n \n\n \n\n \n \n \n \n NDM-CGHR\n \n \n\n \n\n\n
\n \n\n \n \n \nOne trial. Over 47,000 participants. Nearly 200 hospital sites, across six countries. Ten results. Four effective COVID-19 treatments. And behind them all, an army of countless researchers, doctors, nurses, statisticians and supporting staff.
\n \n\n\n \n 24 March 2022\n \n
\n\n \n\n \n\n \n \n \n \n OUCRU\n \n \n\n \n\n\n
\n \n\n \n \n \nEach year on 24 March, World TB Day is commemorated to raise awareness of this devastating and deadly disease. The theme for this year\u2019s World TB Day is \u201cInvest to End TB. Save Lives\u201d, conveying the urgent need to invest resources to ramp up the fight against TB and achieve the commitments to end TB made by global leaders.
\n \n\n\n \n 24 March 2022\n \n
\n\n \n\n \n\n \n \n \n \n MORU\n \n \n \n \n Public Engagement\n \n \n \n \n SMRU\n \n \n\n \n\n\n
\n \n\n \n \n \nIn 2022, tuberculosis (TB) remains a major global health problem, particularly in developing countries. On the Thai-Myanmar border, TB is an important problem among migrants, a vulnerable, very mobile population, with unstable, often difficult living conditions, insecure incomes, and poor access to health services.
\n \n\n\n \n 22 March 2022\n \n
\n\n \n\n \n\n \n \n \n \n MORU\n \n \n \n \n OUCRU\n \n \n\n \n\n\n
\n \n\n \n \n \nA triple artemisinin-based combination therapy (TACT) of artemether-lumefantrine plus amodiaquine (AL+AQ) for uncomplicated falciparum malaria in areas with a high prevalence of artemisinin resistance is a well-tolerated, effective treatment for multidrug-resistant parasites, say a team of MORU-led researchers.
\n \n\n\n \n 22 March 2022\n \n
\n\n \n\n \n\n \n \n \n \n OUCRU\n \n \n \n \n OUCRU-Indonesia\n \n \n \n \n Video\n \n \n\n \n\n\n
\n \n\n \n \n \nIn this video, explore OUCRU's research areas and what questions we are aiming to answer in the next 5 years.
\n \n\n\n \n 18 March 2022\n \n
\n\n \n\n \n\n \n \n \n \n NDM-CGHR\n \n \n\n \n\n\n
\n \n\n \n \n \nThe world\u2019s largest clinical trial investigating treatments for COVID-19 has now launched in Ghana, West Africa. This is the sixth country to take part in RECOVERY, joining Indonesia, Nepal, South Africa, Vietnam, and the United Kingdom.
\n \n\n\n \n 11 March 2022\n \n
\n\n \n\n \n\n \n \n \n \n OUCRU\n \n \n \n \n OUCRU-Indonesia\n \n \n \n \n OUCRU-Nepal\n \n \n \n \n Public Engagement\n \n \n\n \n\n\n
\n \n\n \n \n \nIn the last two years, OUCRU has worked with our partners and collaborators to conduct various research and engagement projects in response to the COVID-19 pandemic. This portfolio provides an overview of all the on-going projects that our entire programme have been working on to contribute to the understanding and management of COVID-19 and its national, regional and global impact.
\n \n\n\n \n 11 March 2022\n \n
\n\n \n\n \n\n \n \n \n \n OUCRU\n \n \n \n \n OUCRU-Indonesia\n \n \n\n \n\n\n
\n \n\n \n \n \nAre you curious about what a leading regional research hub for infectious disease look like? OUCRU is a large-scale research programme with offices in Ho Chi Minh City, Hanoi (Vietnam) and Jakarta (Indonesia). In this video, our leading scientists will take you on a tour of OUCRU's facilities and introduce you to our host institutions: the Hospital for Tropical Diseases (Ho Chi Minh City, Vietnam), the National Hospital for Tropical Diseases (Hanoi, Vietnam), and the Eijkman Institute (Jakarta, Indonesia)
\n \n\n\n \n 11 March 2022\n \n
\n\n \n\n \n\n \n \n \n \n NDM-CGHR\n \n \n\n \n\n\n
\n \n\n \n \n \nThe University of Oxford in collaboration with the University of Maryland School of Medicine has begun recruiting for a Phase I/II trial of a new paratyphoid vaccine in human volunteers in Oxford. In the first study of its kind, after vaccination volunteers will be 'challenged' with paratyphoid to see whether the vaccine can prevent infection.
\n \n\n\n \n 8 March 2022\n \n
\n\n \n\n \n\n \n \n \n \n NDM-CGHR\n \n \n\n \n\n\n
\n \n\n \n \n \nA new malaria study using a very large analysis of pooled individual patient data (IPD) from more than 70,000 patients of all ages, has been published in BMC Medicine by the WorldWide Antimalarial Resistance Network Falciparum Haematology Study Group
\n \n\n\n \n 4 March 2022\n \n
\n\n \n\n \n\n \n \n \n \n OUCRU\n \n \n \n \n OUCRU-Indonesia\n \n \n \n \n OUCRU-Nepal\n \n \n\n \n\n\n
\n \n\n \n \n \nAfter over 30 years of working in infectious disease in Vietnam, Indonesia, and Nepal, OUCRU has developed and established its foothold as a crucial regional research hub in infectious diseases, bridging the gap between research and treatments all over the world. What have we done? How did we do it? And what will OUCRU continue to focus on in the next 5 years?
\n \n\n\n \n 3 March 2022\n \n
\n\n \n\n \n\n \n \n \n \n NDM-CGHR\n \n \n\n \n\n\n
\n \n\n \n \n \nThe Randomised Evaluation of COVID-19 Therapy (RECOVERY) trial has demonstrated that baricitinib, an anti-inflammatory drug normally used to treat rheumatoid arthritis, reduces the risk of death when given to hospitalised patients with severe COVID-19. The benefit was in addition to those of dexamethasone and tocilizumab, two other anti-inflammatory treatments which have previously been shown to reduce the risk of death in these patients.
\n \n\n\n \n 1 March 2022\n \n
\n\n \n\n \n\n \n \n \n \n NDM-CGHR\n \n \n \n \n Video\n \n \n\n \n\n\n
\n \n\n \n \n \nThe University of Oxford has launched a new institute of global research collaboration and excellence, the Pandemic Sciences Institute. It will harness the strong global research collaborations that the University of Oxford has developed over more than forty years to ensure that the world is better equipped to create global and equitable science-driven solutions to prepare for, identify, and counter future pandemic threats.
\n \n\n\n \n 1 March 2022\n \n
\n\n \n\n \n\n \n \n \n \n OUCRU\n \n \n\n \n\n\n
\n \n\n \n \n \nOUCRU Public and Community Engagement Department has compiled a directory of services for Vietnamese communities and people living in Vietnam. Throughout the Covid-19 pandemic, OUCRU has been actively involved in Covid-19 diagnostics, treatment, research, health education, and community engagement. We have worked in collaboration with the Vietnamese Ministry of Health and respected medical and research institutes across Vietnam.
\n \n\n\n \n 18 February 2022\n \n
\n\n \n\n \n\n \n \n \n \n NDM-CGHR\n \n \n\n \n\n\n
\n \n\n \n \n \nStarting October 2022 and based on the MSc in Modelling for Global Health, our new Training Programme in Modelling for Global Health allows participants to select a bespoke set of short courses from the Modelling for Global Health curriculum.
\n \n\n\n \n 18 February 2022\n \n
\n\n \n\n \n\n \n \n \n \n OUCRU\n \n \n\n \n\n\n
\n \n\n \n \n \nOxford University Clinical Research Unit (OUCRU), a leading clinical and public health research unit, and Dragon Capital Group, an established financial institution focused on Vietnam and other Southeast Asian emerging markets, announced a two-year partnership to support the development of high-quality intensive care for those with life-threatening infectious diseases in Vietnam.
\n \n\n\n \n 18 February 2022\n \n
\n\n \n\n \n\n \n \n \n \n NDM-CGHR\n \n \n\n \n\n\n
\n \n\n \n \n \nFrom 1st- 3rd March 2022 the Centre for Tropical Medicine and Global Health will be hosting a demo event to showcase holographic meeting equipment and assess whether this technology offers an advantageous solution to topical issues such as hybrid meetings and international travel whilst also providing opportunities to enhance international communication.
\n \n\n\n \n 8 February 2022\n \n
\n\n \n\n \n\n \n \n \n \n KWTRP\n \n \n\n \n\n\n
\n \n\n \n \n \nResults from a clinical trial completed in Kenya have determined that a safe dose of the antibiotic, fosfomycin, can be used to treat babies with neonatal sepsis. This is a significant development, as there are very few antibiotics specifically licensed to treat multidrug-resistant infections in babies. This research was lead by Dr Christina Obiero and Professor Jay Berkley.
\n \n\n\n \n 25 January 2022\n \n
\n\n \n\n \n\n \n \n \n \n MORU\n \n \n\n \n\n\n
\n \n\n \n \n \nFrom 2002-2018, there has been a steady increase in the places and proportion of infected people reporting validated kelch13 (K13) artemisinin resistance markers, according to a study in The Lancet Microbe. This increase in artemisinin resistance threatens efforts to eliminate malaria in Asia by 2030 \u2014 and control efforts in other endemic regions. The authors say that more consistent data collection, over longer time periods in the same areas, and rapid sharing of data are needed to map the spread of resistance and better inform policy decisions.
\n \n\n\n \n 20 January 2022\n \n
\n\n \n\n \n\n \n \n \n \n MORU\n \n \n \n \n NDM-CGHR\n \n \n\n \n\n\n
\n \n\n \n \n \nAntimicrobial resistance (AMR) is responsible for at least 1.27 million deaths per year \u2014 with over 97,000 deaths in 2019 in SE Asia alone, according to a study published in The Lancet by the Global Research on AntiMicrobial resistance (GRAM) project, who urged urgent action from policymakers and health communities to avoid further preventable deaths.
\n \n\n\n \n 19 January 2022\n \n
\n\n \n\n \n\n \n \n \n \n Awards & Appointments\n \n \n \n \n KWTRP\n \n \n \n \n Video\n \n \n\n \n\n\n
\n \n\n \n \n \nRoyal Society 2021 Africa Prize lecture from Professor George Warimwe. More than 70% of emerging infectious diseases (including viruses) are zoonotic, meaning they are acquired from animals, with some causing serious illness and death in humans as well as the animal host. But, what if we could immunise both humans and animals with the same vaccine?
\n \n\n\n \n 31 December 2021\n \n
\n\n \n\n \n\n \n \n \n \n Awards & Appointments\n \n \n \n \n General\n \n \n\n \n\n\n
\n \n\n \n \n \nTwo RECOVERY Trial team members have been recognised in the New Year Honours list 2022. RECOVERY Trial coordinator, Professor Richard Haynes, has been appointed Member of the Order of the British Empire (MBE) for services to Global Health, and Senior Clinical Trial Manager, Lucy Fletcher, has been appointed MBE for services to Clinical Trials. The New Year Honours list recognises outstanding achievements by a wide range of extraordinary people from across the United Kingdom. People are awarded honours for achievements in their field of work (including health, education, science and technology), as well as for making a difference to their community.
\n \n\n\n \n 20 December 2021\n \n
\n\n \n\n \n\n \n \n \n \n Awards & Appointments\n \n \n \n \n COMRU\n \n \n \n \n MORU\n \n \n \n \n NDM-CGHR\n \n \n\n \n\n\n
\n \n\n \n \n \nIn the 2021 Oxford Recognition of Distinction round, four MORU colleagues were awarded Full Professor title.
\n \n\n\n \n 10 December 2021\n \n
\n\n \n\n \n\n \n \n \n \n NDM-CGHR\n \n \n\n \n\n\n
\n \n\n \n \n \nThe world\u2019s largest clinical trial investigating treatments for COVID-19 has now launched in South Africa, with the first patient recruited today. This is the fifth country to take part in RECOVERY, joining Nepal, Indonesia, Vietnam, and the United Kingdom.
\n \n\n\n \n 26 November 2021\n \n
\n\n \n\n \n\n \n \n \n \n Awards & Appointments\n \n \n \n \n NDM-CGHR\n \n \n\n \n\n\n
\n \n\n \n \n \nThe RECOVERY Trial has been awarded the 2021 Times Higher Education (THE) Award in the \u2018Research Project of the Year: STEM\u2019 category.
\n \n\n\n \n 24 November 2021\n \n
\n\n \n\n \n\n \n \n \n \n MORU\n \n \n \n \n SMRU\n \n \n\n \n\n\n
\n \n\n \n \n \nFeatured in Nature, Victor Chaumeau collects mosquitoes in Myanmar to better understand how to control malaria.
\n \n\n\n \n 24 November 2021\n \n
\n\n \n\n \n\n \n \n \n \n MORU\n \n \n \n \n NDM-CGHR\n \n \n\n \n\n\n
\n \n\n \n \n \nPatients in north Africa and the Middle East are using antibiotics in sharply rising quantities far beyond the global average, raising concerns over the escalating risks of resistance to medicines to treat bacterial infections. Estimated antibiotic consumption for 204 countries between 2000 and 2018 shows a 46 per cent increase in global antibiotic usage, with a surge in nations including India and Vietnam.
\n \n\n\n \n 19 November 2021\n \n
\n\n \n\n \n\n \n \n \n \n KWTRP\n \n \n \n \n MORU\n \n \n \n \n OUCRU\n \n \n \n \n Public Engagement\n \n \n\n \n\n\n
\n \n\n \n \n \nA downloadable resource for educators, health & research professionals to help develop young peoples\u2019 understanding of AMR and positive actions they can take to mitigate it.
\n \n\n\n \n 19 November 2021\n \n
\n\n \n\n \n\n \n \n \n \n Awards & Appointments\n \n \n \n \n NDM-CGHR\n \n \n\n \n\n\n
\n \n\n \n \n \nProfessor Paul Newton was announced new Distinguished International Fellow at the ASTMH Annual Meeting Awards Ceremony on the 17th November. This distinction formally recognizes individuals who have made eminent contributions to a particular aspect of tropical medicine or hygiene.
\n \n\n\n \n 18 November 2021\n \n
\n\n \n\n \n\n \n \n \n \n MORU\n \n \n\n \n\n\n
\n \n\n \n \n \nTo mark WHO World Antimicrobial Awareness Week, 18-24 Nov 2021, and help reduce the overuse of antibiotics, MORU researchers have released a new, easy to use online tool \u2013 Antibiotic Footprint Calculator \u2013 that could make an important contribution in the fight against antimicrobial resistance (AMR), one of the world\u2019s most significant emerging threats to public health.
\n \n\n\n \n 16 November 2021\n \n
\n\n \n\n \n\n \n \n \n \n OUCRU\n \n \n \n \n OUCRU-Indonesia\n \n \n \n \n Public Engagement\n \n \n \n \n Video\n \n \n\n \n\n\n
\n \n\n \n \n \nUntil recently, Plasmodium falciparum dominated the malaria research landscape, and Plasmodium vivax infection was considered benign and inconsequential. We now know that this is not true: if not properly diagnosed and treated, P. vivax can lead to life-threatening syndromes and death. Professor Kevin Baird from EOCRU in Jakarta, Indonesia talks to OutBreak News Today
\n \n\n\n \n 12 November 2021\n \n
\n\n \n\n \n\n \n \n \n \n MORU\n \n \n \n \n NDM-CGHR\n \n \n\n \n\n\n
\n \n\n \n \n \nGlobal antibiotic consumption rates increased by 46 percent in the last two decades, according to the first study to provide longitudinal estimates for human antibiotic consumption covering 204 countries from 2000 to 2018, published in Lancet Planetary Health by the Global Research on Antimicrobial Resistance (GRAM) Project.
\n \n\n\n \n 10 November 2021\n \n
\n\n \n\n \n\n \n \n \n \n OUCRU\n \n \n \n \n OUCRU-Indonesia\n \n \n \n \n OUCRU-Nepal\n \n \n\n \n\n\n
\n \n\n \n \n \nDespite unprecedented disruptions caused globally by SARS-Cov-2, OUCRU has responded remarkably and addressed almost every important aspect of the pandemic, from its societal impact to viral genomic surveillance and COVID-19 therapy
\n \n\n\n \n 2 November 2021\n \n
\n\n \n\n \n\n \n \n \n \n NDM-CGHR\n \n \n \n \n OUCRU\n \n \n \n \n OUCRU-Indonesia\n \n \n\n \n\n\n
\n \n\n \n \n \nA new, extensive systematic review has identified significant research gaps in the treatment of scrub typhus which could be improved by developing a database for individual participant data (IPD) to enable more detailed analyses to address important knowledge gaps such as the optimum dosing for children and to improve patient outcomes.
\n \n\n\n \n 26 October 2021\n \n
\n\n \n\n \n\n \n \n \n \n OUCRU\n \n \n\n \n\n\n
\n \n\n \n \n \nHopes that tamoxifen could improve survival for a deadly form of fungal meningitis have been dashed by the results of a clinical trial conducted by University of Oxford researchers and published today in eLife.
\n \n\n\n \n 22 October 2021\n \n
\n\n \n\n \n\n \n \n \n \n OUCRU\n \n \n\n \n\n\n
\n \n\n \n \n \nUsing cutting-edge genomic sequencing techniques, researchers at the University of Oxford have identified almost all the genomic variation that gives people resistance to 13 of the most common tuberculosis drug treatments.
\n \n\n\n \n 14 October 2021\n \n
\n\n \n\n \n\n \n \n \n \n Awards & Appointments\n \n \n \n \n NDM-CGHR\n \n \n\n \n\n\n
\n \n\n \n \n \nThe Faculty of Public Health has awarded its prestigious Alwyn Smith Prize to Professor Sir Peter Horby for 2020/2021 in recognition of his outstanding service to public health as a global leader in epidemic science.
\n \n\n\n \n 12 October 2021\n \n
\n\n \n\n \n\n \n \n \n \n Awards & Appointments\n \n \n \n \n KWTRP\n \n \n\n \n\n\n
\n \n\n \n \n \nPeter Macharia is a spatial epidemiologist and a postdoc interested in disease mapping, healthcare access and mapping population vulnerabilities at KEMRI Wellcome. He received the RSTMH 2021 Emerging Leader Award, which recognises significant contributions in leadership, mentoring and capacity building in those who are early in their careers.
\n \n\n\n \n 11 October 2021\n \n
\n\n \n\n \n\n \n \n \n \n LOMWRU\n \n \n \n \n MORU\n \n \n \n \n NDM-CGHR\n \n \n\n \n\n\n
\n \n\n \n \n \nA series of papers which reviewed portable devices to detect poor quality medicines has concluded major gaps in scientific evidence remain a key barrier for regulators to implement surveillance systems using such devices.
\n \n\n\n \n 11 October 2021\n \n
\n\n \n\n \n\n \n \n \n \n OUCRU\n \n \n \n \n OUCRU-Indonesia\n \n \n\n \n\n\n
\n \n\n \n \n \nThe malaria parasite Plasmodium vivax causes frequent, chronic infections that represent a major unrecognized burden on global health, according to a review by Kevin Baird of the Eijkman-Oxford Clinical Research Unit in Indonesia and Katherine Battle of the Institute for Disease Modeling in the United States
\n \n\n